|
5 of 8 Sites Now Recruiting for ZEN-3694/Enzalutamid... Trial
|
3
|
Zenith Epigenetics
|
Feb 23, 2017 03:18PM
|
|
Re: p-values : are correct
|
6
|
Resverlogix Corp.
|
Feb 24, 2017 09:33AM
|
|
Re: p-values : are correct
|
4
|
Resverlogix Corp.
|
Feb 24, 2017 12:03PM
|
|
Re: ... Looking Ahead...
|
7
|
Resverlogix Corp.
|
Feb 25, 2017 02:14PM
|
|
Resverlogix: The Science Is Getting 'BETter' For RVX208
|
3
|
Resverlogix Corp.
|
Feb 27, 2017 11:31AM
|
|
BET inhibitors promising therapy for rare pediatric brain tumor
|
5
|
Zenith Epigenetics
|
Feb 28, 2017 12:40PM
|
|
Re: Broker Meeting 23 Feb
|
4
|
Resverlogix Corp.
|
Mar 01, 2017 12:31PM
|
|
Re: Broker Meeting 23 Feb
|
3
|
Zenith Epigenetics
|
Mar 01, 2017 12:37PM
|
|
Re: BET inhibitors promising therapy for rare pediatric brain tumor
|
4
|
Zenith Epigenetics
|
Mar 01, 2017 12:48PM
|
|
Re: Broker Meeting 23 Feb
|
2
|
Resverlogix Corp.
|
Mar 01, 2017 12:58PM
|
|
Re: Broker Meeting 23 Feb
|
2
|
Resverlogix Corp.
|
Mar 01, 2017 02:01PM
|
|
New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
|
3
|
Zenith Epigenetics
|
Mar 02, 2017 10:51AM
|
|
Re: Safety and Efficacy
|
7
|
Resverlogix Corp.
|
Mar 03, 2017 10:00AM
|
|
Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
|
3
|
Zenith Epigenetics
|
Mar 03, 2017 10:20AM
|
|
Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
|
5
|
Zenith Epigenetics
|
Mar 03, 2017 01:10PM
|
|
Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
|
3
|
Zenith Epigenetics
|
Mar 03, 2017 02:07PM
|
|
Re: Safety and Efficacy
|
2
|
Resverlogix Corp.
|
Mar 03, 2017 06:20PM
|
|
Re: Gluten foods - Causing inflamation - Epigenetics.
|
4
|
Resverlogix Corp.
|
Mar 05, 2017 04:15PM
|
|
2 events this week
|
3
|
Resverlogix Corp.
|
Mar 05, 2017 06:07PM
|
|
Re: 2 events this week
|
4
|
Resverlogix Corp.
|
Mar 06, 2017 10:49PM
|
